Back

Impact of age on implementation and tolerability of guideline-directed medical therapy in heart failure with reduced ejection fraction

29 August 2026 (17:40 - 17:50)
Organised by: Logo
Congress Presentation Part of: Targetting the pathophysiology of HFrEF Heart Failure with Reduced Ejection Fraction (HFrEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mrs Marielle Wilde

Erasmus University Medical Centre, Rotterdam (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
GenePHIT Phase 2 baseline characteristics: a double blind, placebo-controlled trial to assess safety and efficacy of AB-1002 gene therapy in heart failure with reduced ejection fraction
Doctor T. Henry (Cincinnati, US)
Abstract Slides Video
Presentation thumbnail
The mechanical strength of the myocardium in patients with heart failure is primarily determined by the collagen fiber content
Doctor T. Shi (Xi'an, CN)
Abstract Slides Video
Presentation thumbnail
Myocardial scar burden, not mechanical dyssynchrony or strain, dictates recovery potential in HFrEF: a CMR study
Doctor C. Yang (Shanghai, CN)
Abstract Slides
Presentation thumbnail
Apolipoprotein B and reverse remodeling in ischemic heart failure.
Assistant Professor I. Rodean (Targu Mures, RO)
Abstract Slides

Access the full session

Session thumbnail
Targetting the pathophysiology of HFrEF
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 17:40 CET
You may be interested in
thumbnail
Congress Presentation
Therapeutic optimization in a geriatric population with heart failure with reduced ejection fraction: the challenges and the benefits
29 June 2021
thumbnail
Webinar
Implementation of therapy in heart failure
22 November 2022
thumbnail
Congress Presentation
Guideline-directed medical therapy use in patients with incident comorbid heart failure and chronic kidney disease (The CaRe Study)
1 September 2025
thumbnail
Congress Presentation
Age differences in prescribing guideline-directed medical treatment in heart failure with mildly reduced and reduced ejection fraction
13 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources